Post-marketing Study Assessing the Long-Term Safety of Abatacept

Trial Profile

Post-marketing Study Assessing the Long-Term Safety of Abatacept

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 24 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 18 Nov 2014 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017 as per ClinicalTrails.gov record.
    • 18 Nov 2014 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017 as per ClinicalTrails.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top